Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRACE Trial: 90Y-RE vs TACE-DEB for HCC
NCT01381211Phase 2Terminated
- Sponsor
- Ghent University Hospital
- Start
- Sep 2011
- Primary completion
- Mar 2018
- Modality
- Nanoparticles, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of yttrium-90 radioembolization in hepatocellular carcinoma (HCC) (2 arms), sponsored by Ghent University Hospital. Primary endpoint: Time to Progression at 2 years. Started Sep 2011; status: terminated.
02
Drugs
yttrium-90 radioembolization
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01381211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01381211.